Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 3

The DOI matches its Crossref record; the references it cites are not checked yet.

Acromegaly diagnosis

Yogi-Morren, Divya, Chanson, Philippe·2026·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/clinem/dgag189
Open this paper in CoChat — free account

Abstract

The clinical presentation of acromegaly reflects systemic effects of chronic growth hormone (GH) and insulin-like growth factor 1 (IGF-I) excess. Diagnostic delay frequently ranges from 6 to 10 years. While classical manifestations such as acral enlargement and facial coarsening are diagnostically important, many patients initially develop nonspecific symptoms, including sleep apnea, carpal tunnel syndrome, arthralgia, and metabolic disturbances. The lack of symptom/comorbidity specificity highlights the need for improved screening strategies, particularly for patients without overt acral changes. Comorbidity cluster analyses, potentially supported by artificial intelligence, may facilitate earlier identification, prompting biochemical confirmation of the diagnosis. Biochemical evaluation has benefited from advances in hormone assay harmonization and the establishment of robust age-adjusted reference ranges. Serum IGF-I is the preferred initial screening test due to its stability and reflection of integrated GH secretion. However, interpretation of assay values should consider age, sex, assay variability, and confounding conditions such as diabetes, liver or renal disease, obesity, pregnancy, and estrogen exposure. For discordant biochemical and clinical findings, it is recommended to repeat IGF-I and to measure GH during an oral glucose tolerance test (OGTT). Although random GH levels are often elevated and correlate with somatotroph adenoma size, GH suppression during OGTT is the gold-standard confirmatory test, especially in patients with borderline results. The use of ultrasensitive GH assays has lowered the recommended nadir GH cut-off threshold to ∼0.4 µg/L, with assay-specific considerations. Advances in high-resolution MRI and PET/MRI, alongside AI-driven facial recognition, electronic medical record analysis, and radiomics, offer promising avenues for earlier and more accurate diagnosis of acromegaly.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/clinem/dgag189

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists haven’t been fetched yet

Cited by 3

Research works printed but not linked: 116

  1. Chanson, 2014, Acromegaly, Handb Clin Neurol, 124, 197, 10.1016/B978-0-444-59602-4.00014-9 · DOI
  2. Fleseriu, 2022, Acromegaly: pathogenesis, diagnosis, and management, Lancet Diabetes Endocrinol, 10, 804, 10.1016/S2213-8587(22)00244-3 · DOI · Paper page
  3. Giustina, 2025, Acromegaly, N Engl J Med, 393, 1926, 10.1056/NEJMra2409076 · DOI · Paper page
  4. Kamenický, 2014, Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications, Endocr Rev, 35, 234, 10.1210/er.2013-1071 · DOI · Paper page
  5. Crisafulli, 2021, Global epidemiology of acromegaly: a systematic review and meta-analysis, Eur J Endocrinol, 185, 251, 10.1530/EJE-21-0216 · DOI
  6. Dekkers, 2008, Mortality in acromegaly: a metaanalysis, J Clin Endocrinol Metab, 93, 61, 10.1210/jc.2007-1191 · DOI · Paper page
  7. Esposito, 2020, Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality, Eur J Endocrinol, 182, 523, 10.1530/EJE-20-0019 · DOI · Paper page
  8. Holdaway, 2008, A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly, Eur J Endocrinol, 159, 89, 10.1530/EJE-08-0267 · DOI · Paper page
  9. Kreitschmann-Andermahr, 2016, Diagnosis and management of acromegaly: the patient's perspective, Pituitary, 19, 268, 10.1007/s11102-015-0702-1 · DOI
  10. Nachtigall, 2008, Changing patterns in diagnosis and therapy of acromegaly over two decades, J Clin Endocrinol Metab, 93, 2035, 10.1210/jc.2007-2149 · DOI
  11. Petrossians, 2017, Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) database, Endocr Relat Cancer, 24, 505, 10.1530/ERC-17-0253 · DOI · Paper page
  12. Reid, 2010, Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed, Clin Endocrinol (Oxf), 72, 203, 10.1111/j.1365-2265.2009.03626.x · doi:10.1111/j.1365-2265.2009.03626.x
  13. Caron, 2019, Signs and symptoms of acromegaly at diagnosis: the physician's and the patient’s perspectives in the ACRO-POLIS study, Endocrine, 63, 120, 10.1007/s12020-018-1764-4 · DOI
  14. Clemmons, 2011, Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays, Clin Chem, 57, 555, 10.1373/clinchem.2010.150631 · DOI · Paper page
  15. Bidlingmaier, 2014, Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations, J Clin Endocrinol Metab, 99, 1712, 10.1210/jc.2013-3059 · DOI · Paper page
  16. Chanson, 2016, Reference values for IGF-I serum concentrations: comparison of six immunoassays, J Clin Endocrinol Metab, 101, 3450, 10.1210/jc.2016-1257 · DOI
  17. Schilbach, 2019, Determinants of the growth hormone nadir during oral glucose tolerance test in adults, Eur J Endocrinol, 181, 55, 10.1530/EJE-19-0139 · DOI
  18. Clemmons, 2023, Interpreting growth hormone and IGF-I results using modern assays and reference ranges for the monitoring of treatment effectiveness in acromegaly, Front Endocrinol (Lausanne), 14, 10.3389/fendo.2023.1266339 · doi:10.3389/fendo.2023.1266339
  19. Clemmons, 2024, IGF-I assay methods and biologic variability: evaluation of acromegaly treatment response, Eur J Endocrinol, 191, R1, 10.1093/ejendo/lvae065 · doi:10.1093/ejendo/lvae065
  20. Huynh, 2025, Novel imaging modalities in the evaluation of patients with pituitary adenomas, Endocrinol Metab Clin North Am, 54, 549, 10.1016/j.ecl.2025.08.001 · DOI
  21. Qiao, 2025, Artificial intelligence in pituitary disease, Endocrinol Metab Clin North Am, 54, 715, 10.1016/j.ecl.2025.06.004 · DOI
  22. Agosti, 2025, Radiomics in pituitary adenomas: a systematic review of clinical applications and predictive models, J Clin Med, 14, 6595, 10.3390/jcm14186595 · DOI
  23. Slagboom, 2023, Prevalence of clinical signs, symptoms and comorbidities at diagnosis of acromegaly: a systematic review in accordance with PRISMA guidelines, Pituitary, 26, 319, 10.1007/s11102-023-01322-7 · DOI
  24. Crisafulli, 2022, Development and testing of diagnostic algorithms to identify patients with acromegaly in Southern Italian claims databases, Sci Rep, 12, 15843, 10.1038/s41598-022-20295-4 · doi:10.1038/s41598-022-20295-4
  25. Crisafulli, 2024, Machine learning-based algorithms applied to drug prescriptions and other healthcare services in the Sicilian claims database to identify acromegaly as a model for the earlier diagnosis of rare diseases, Sci Rep, 14, 6186, 10.1038/s41598-024-56240-w · doi:10.1038/s41598-024-56240-w
  26. Slagboom, 2025, Acromegaly: is earlier diagnosis possible? Exploration of a screening algorithm to select high-risk patients, Endocr Metab Sci, 17, 100223, 10.1016/j.endmts.2025.100223 · doi:10.1016/j.endmts.2025.100223
  27. Lenders, 2020, Management of endocrine disease: does gender matter in the management of acromegaly?, Eur J Endocrinol, 182, R67, 10.1530/EJE-19-1023 · DOI
  28. Giustina, 2000, Criteria for cure of acromegaly: a consensus statement, J Clin Endocrinol Metab, 85, 526
  29. Giustina, 2010, A consensus on criteria for cure of acromegaly, J Clin Endocrinol Metab, 95, 3141, 10.1210/jc.2009-2670 · DOI · Paper page
  30. Katznelson, 2014, Acromegaly: an endocrine society clinical practice guideline, J Clin Endocrinol Metab, 99, 3933, 10.1210/jc.2014-2700 · DOI · Paper page
  31. Giustina, 2024, Consensus on criteria for acromegaly diagnosis and remission, Pituitary, 27, 7, 10.1007/s11102-023-01360-1 · DOI · Paper page
  32. Sabbah, 2021, Reference values for IGF-I serum concentration in an adult population: use of the VARIETE cohort for two new immunoassays, Endocr Connect, 10, 1027, 10.1530/EC-21-0175 · DOI
  33. Shah, 2025, Normative data for insulin-like growth factor-1 and insulin-like growth factor binding protein-3 and their determinants in healthy adult males from India: the INDIIGo study, Sci Rep, 15, 41340, 10.1038/s41598-025-25235-6 · doi:10.1038/s41598-025-25235-6
  34. Bidlingmaier, 2022, Differences in the distribution of IGF-I concentrations between European and US populations, J Endocr Soc, 6, 10.1210/jendso/bvac081 · DOI
  35. Mavromati, 2017, Classification of patients with GH disorders may vary according to the IGF-I assay, J Clin Endocrinol Metab, 102, 2844, 10.1210/jc.2017-00202 · DOI
  36. Carmichael, 2009, The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly, J Clin Endocrinol Metab, 94, 523, 10.1210/jc.2008-1371 · doi:10.1210/jc.2008-1371
  37. Hage, 2019, Growth hormone response to oral glucose load: from normal to pathological conditions, Neuroendocrinology, 108, 244, 10.1159/000497214 · DOI
  38. Trainer, 2002, Editorial: acromegaly–consensus, what consensus?, J Clin Endocrinol Metab, 87, 3534
  39. Melmed, 2018, A consensus statement on acromegaly therapeutic outcomes, Nat Rev Endocrinol, 14, 552, 10.1038/s41574-018-0058-5 · DOI · Paper page
  40. Arafat, 2008, Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index, J Clin Endocrinol Metab, 93, 1254, 10.1210/jc.2007-2084 · DOI
  41. Hage, 2018, Genomic alterations and complex subclonal architecture in sporadic GH-secreting pituitary adenomas, J Clin Endocrinol Metab, 103, 1929, 10.1210/jc.2017-02287 · DOI
  42. Lacroix, 2024, Aberrant hormone receptors regulate a wide spectrum of endocrine tumors, Lancet Diabetes Endocrinol, 12, 837, 10.1016/S2213-8587(24)00200-6 · DOI
  43. Hage, 2021, Management of endocrine disease: etiology and outcome of acromegaly in patients with a paradoxical GH response to glucose, Eur J Endocrinol, 184, R261, 10.1530/EJE-20-1448 · doi:10.1530/eje-20-1448
  44. Vilar, 2024, “Micromegaly”: acromegaly with apparently normal GH, an entity on its own?, Best Pract Res Clin Endocrinol Metab, 38, 10.1016/j.beem.2024.101878 · doi:10.1016/j.beem.2024.101878
  45. Frara, 2016, Current and emerging aspects of diabetes mellitus in acromegaly, Trends Endocrinol Metab, 27, 470, 10.1016/j.tem.2016.04.014 · DOI
  46. Schweizer, 2021, Soluble alpha klotho in acromegaly: comparison with traditional markers of disease activity, J Clin Endocrinol Metab, 106, e2887, 10.1210/clinem/dgab257 · DOI
  47. Schweizer, 2025, Soluble alpha klotho-impact of biological variables and reference intervals for adults, Eur J Endocrinol, 192, 631, 10.1093/ejendo/lvaf093 · doi:10.1093/ejendo/lvaf093
  48. Lim, 2007, Acromegaly associated with type 2 diabetes showing normal IGF-1 levels under poorly controlled glycemia, Endocr J, 54, 537, 10.1507/endocrj.K06-083 · doi:10.1507/endocrj.k06-083
  49. Chakraborty, 2016, Pseudoacromegaly in congenital generalised lipodystrophy (Berardinelli-Seip syndrome), BMJ Case Rep, 2016, 10.1136/bcr-2016-214493 · doi:10.1136/bcr-2016-214493
  50. Chakraborty, 2017, Pseudoacromegaly: an unusual presenting manifestation of long-standing undiagnosed primary hypothyroidism, Postgrad Med J, 93, 639, 10.1136/postgradmedj-2017-134963 · DOI
  51. Marques, 2022, Approach to the patient with pseudoacromegaly, J Clin Endocrinol Metab, 107, 1767, 10.1210/clinem/dgab789 · DOI
  52. Marques, 2024, Pseudoacromegaly-a challenging entity in the endocrine clinic: a systematic review, Clin Endocrinol (Oxf), 100, 542, 10.1111/cen.15053 · doi:10.1111/cen.15053
  53. Junn, 2025, Congress of neurological surgeons systematic review and evidence-based guidelines for the role of imaging for patients with functioning pituitary adenomas, Neurosurgery, 97, S15, 10.1227/neu.0000000000003607 · doi:10.1227/neu.0000000000003607
  54. Hanzu, 2025, Multimodal advanced imaging for precision medicine in pituitary tumors, Eur J Endocrinol, 193, R1, 10.1093/ejendo/lvaf144 · doi:10.1093/ejendo/lvaf144
  55. Bonneville, 2016, MRI of the Pituitary Gland. Vol 1. 1st ed, 10.1007/978-3-319-29043-0 · doi:10.1007/978-3-319-29043-0
  56. MacFarlane, 2020, Advances in the imaging of pituitary tumors, Endocrinol Metab Clin North Am, 49, 357, 10.1016/j.ecl.2020.06.002 · DOI
  57. Potorac, 2015, Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences, Endocr Relat Cancer, 22, 169, 10.1530/ERC-14-0305 · doi:10.1530/erc-14-0305
  58. Bakhtiar, 2014, Geometric survey on magnetic resonance imaging of growth hormone producing pituitary adenoma, Pituitary, 17, 142, 10.1007/s11102-013-0479-z · doi:10.1007/s11102-013-0479-z
  59. Heck, 2016, Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly, Endocrine, 52, 333, 10.1007/s12020-015-0766-8 · doi:10.1007/s12020-015-0766-8
  60. Potorac, 2016, T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly, Endocr Relat Cancer, 23, 871, 10.1530/ERC-16-0356 · DOI
  61. Puig-Domingo, 2010, Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure, J Clin Endocrinol Metab, 95, 4973, 10.1210/jc.2010-0573 · doi:10.1210/jc.2010-0573
  62. Ilie, 2022, Predictive factors of somatostatin receptor ligand response in acromegaly-a prospective study, J Clin Endocrinol Metab, 107, 2982, 10.1210/clinem/dgac512 · doi:10.1210/clinem/dgac512
  63. Testud, 2025, Review of 7T MRI imaging of pituitary microadenomas: are we there yet?, Neuroradiology, 67, 529, 10.1007/s00234-025-03554-9 · DOI
  64. Haberbosch, 2024, Dual role for l-[methyl-(11)C]-methionine PET in acromegaly: confirming remission and detecting recurrence, J Nucl Med, 65, 327, 10.2967/jnumed.123.266446 · doi:10.2967/jnumed.123.266446
  65. Haberbosch, 2024, Real-world experience with 11C-methionine positron emission tomography in the management of acromegaly, Eur J Endocrinol, 190, 307, 10.1093/ejendo/lvae028 · doi:10.1093/ejendo/lvae028
  66. Pruis, 2024, [(18)F]FET PET/MRI: an accurate technique for detection of small functional pituitary tumors, J Nucl Med, 65, 688, 10.2967/jnumed.123.266853 · doi:10.2967/jnumed.123.266853
  67. Bakker, 2024, (18)F-fluoro-ethyl-tyrosine PET co-registered with MRI in patients with persisting acromegaly, Clin Endocrinol (Oxf), 101, 142, 10.1111/cen.15079 · doi:10.1111/cen.15079
  68. Rosario, 2011, Frequency of acromegaly in adults with diabetes or glucose intolerance and estimated prevalence in the general population, Pituitary, 14, 217, 10.1007/s11102-010-0281-0 · DOI
  69. Suda, 2015, The prevalence of acromegaly in hospitalized patients with type 2 diabetes, Endocr J, 62, 53, 10.1507/endocrj.EJ14-0254 · DOI
  70. Rosario, 2012, Screening for acromegaly by application of a simple questionnaire evaluating the enlargement of extremities in adult patients seen at primary health care units, Pituitary, 15, 179, 10.1007/s11102-011-0302-7 · doi:10.1007/s11102-011-0302-7
  71. Galerneau, 2016, Acromegaly in sleep apnoea patients: a large observational study of 755 patients, Eur Respir J, 48, 1489, 10.1183/13993003.01229-2016 · doi:10.1183/13993003.01229-2016
  72. Heinrich, 2018, IGF-1-based screening reveals a low prevalence of acromegaly in patients with obstructive sleep apnea, Endocrine, 60, 317, 10.1007/s12020-018-1538-z · DOI
  73. Schneider, 2008, High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels, Clin Endocrinol (Oxf), 69, 432, 10.1111/j.1365-2265.2008.03221.x · DOI
  74. Attal, 2018, Screening of acromegaly in adults with obstructive sleep apnea: is it worthwhile?, Endocrine, 61, 4, 10.1007/s12020-018-1618-0 · doi:10.1007/s12020-018-1618-0
  75. Wilson, 1968, Principles and Practice of Screening for Disease. Public Health Papers. Vol 34, 22
  76. Lavrentaki, 2017, Epidemiology of acromegaly: review of population studies, Pituitary, 20, 4, 10.1007/s11102-016-0754-x · doi:10.1007/s11102-016-0754-x
  77. Giustina, 2020, A consensus on the diagnosis and treatment of acromegaly comorbidities: an update, J Clin Endocrinol Metab, 105, 10.1210/clinem/dgz096 · DOI · Paper page
  78. Prencipe, 2016, ACROSCORE: a new and simple tool for the diagnosis of acromegaly, a rare and underdiagnosed disease, Clin Endocrinol (Oxf), 84, 380, 10.1111/cen.12959 · DOI
  79. Broder, 2017, An approach to using data mining to support early identification of acromegaly, Endocr Pract, 23, 422, 10.4158/EP161575.OR · doi:10.4158/ep161575.or
  80. Kong, 2018, Automatic detection of acromegaly from facial photographs using machine learning methods, EBioMedicine, 27, 94, 10.1016/j.ebiom.2017.12.015 · DOI
  81. Miller, 2011, Early diagnosis of acromegaly: computers vs clinicians, Clin Endocrinol (Oxf), 75, 226, 10.1111/j.1365-2265.2011.04020.x · DOI
  82. Schneider, 2011, A novel approach to the detection of acromegaly: accuracy of diagnosis by automatic face classification, J Clin Endocrinol Metab, 96, 2074, 10.1210/jc.2011-0237 · DOI
  83. Guo, 2018, 3D facial analysis in acromegaly: gender-specific features and clinical correlations, Front Endocrinol (Lausanne), 9, 722, 10.3389/fendo.2018.00722 · doi:10.3389/fendo.2018.00722
  84. Meng, 2020, Identifying facial features and predicting patients of acromegaly using three-dimensional imaging techniques and machine learning, Front Endocrinol (Lausanne), 11, 492, 10.3389/fendo.2020.00492 · doi:10.3389/fendo.2020.00492
  85. Kizilgul, 2023, Real-time detection of acromegaly from facial images with artificial intelligence, Eur J Endocrinol, 188, 158, 10.1093/ejendo/lvad005 · DOI
  86. Kocaman, 2026, Facial analysis in acromegaly using machine learning: towards earlier diagnosis, J Clin Endocrinol Metab, 111, e892, 10.1210/clinem/dgaf477 · doi:10.1210/clinem/dgaf477
  87. Rashwan, 2025, Acromegaly facial changes analysis using last generation artificial intelligence methodology: the AcroFace system, Pituitary, 28, 50, 10.1007/s11102-025-01515-2 · DOI
  88. Giustina, 2025, Artificial intelligence in acromegaly: why, when and how, Pituitary, 28, 66, 10.1007/s11102-025-01534-z · DOI
  89. Bogazzi, 2010, Analysis of voice in patients with untreated active acromegaly, J Endocrinol Invest, 33, 178, 10.1007/BF03346578 · doi:10.1007/bf03346578
  90. Vouzouneraki, 2025, Digital voice analysis as a biomarker of acromegaly, J Clin Endocrinol Metab, 110, 983, 10.1210/clinem/dgae689 · doi:10.1210/clinem/dgae689
  91. Sulu, 2022, Machine learning as a clinical decision support tool for patients with acromegaly, Pituitary, 25, 486, 10.1007/s11102-022-01216-0 · DOI
  92. Assié, 2025, EndoCompass project: artificial intelligence in endocrinology, Horm Res Paediatr, 98, 208
  93. Assié, 2024, Artificial intelligence in endocrinology: on track toward great opportunities, J Clin Endocrinol Metab, 109, e1462, 10.1210/clinem/dgae154 · DOI
  94. Kropf, 2013, Functional evaluation of the joints in acromegalic patients and associated factors, Clin Rheumatol, 32, 991, 10.1007/s10067-013-2219-1 · DOI
  95. Preo, 2022, The role of the dentist and orthodontist in recognizing oro-facial manifestations of acromegaly: a questionnaire-based study, Pituitary, 25, 159, 10.1007/s11102-021-01183-y · doi:10.1007/s11102-021-01183-y
  96. Wiśniewska, 2025, Collaboration between endocrinologists and dentists in the care of patients with acromegaly-a narrative review, J Clin Med, 14, 5511, 10.3390/jcm14155511 · doi:10.3390/jcm14155511
  97. Wolf, 2025, Cardiomyopathy in patients with acromegaly—not truly a concern anymore?, J Clin Endocrinol Metab, 110, 2718, 10.1210/clinem/dgaf338 · DOI
  98. Fainstein-Day, 2024, The clinical and biochemical spectrum of ectopic acromegaly, Best Pract Res Clin Endocrinol Metab, 38, 101877, 10.1016/j.beem.2024.101877 · doi:10.1016/j.beem.2024.101877
  99. Melmed, 1985, Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet-cell tumor, N Engl J Med, 312, 9, 10.1056/NEJM198501033120103 · doi:10.1056/nejm198501033120103
  100. Biswal, 2008, Acromegaly caused by ectopic growth hormone: a rare manifestation of a bronchial carcinoid, Ann Thorac Surg, 85, 330, 10.1016/j.athoracsur.2007.06.072 · doi:10.1016/j.athoracsur.2007.06.072
  101. Krug, 2016, Acromegaly in a patient with a pulmonary neuroendocrine tumor: case report and review of current literature, BMC Res Notes, 9, 326, 10.1186/s13104-016-2132-1 · doi:10.1186/s13104-016-2132-1
  102. Ozkaya, 2015, Ectopic acromegaly due to a growth hormone-secreting neuroendocrine-differentiated tumor developed from ovarian mature cystic teratoma, Wien Klin Wochenschr, 127, 491, 10.1007/s00508-015-0775-x · doi:10.1007/s00508-015-0775-x
  103. Beuschlein, 2000, Acromegaly caused by secretion of growth hormone by a non-Hodgkin's lymphoma, N Engl J Med, 342, 1871, 10.1056/NEJM200006223422504 · doi:10.1056/nejm200006223422504
  104. Garby, 2012, Clinical characteristics and outcome of acromegaly induced by ectopic secretion of growth hormone-releasing hormone (GHRH): a French nationwide series of 21 cases, J Clin Endocrinol Metab, 97, 2093, 10.1210/jc.2011-2930 · doi:10.1210/jc.2011-2930
  105. Al-Salameh, 2021, Clinical aspects of multiple endocrine neoplasia type 1, Nat Rev Endocrinol, 17, 207, 10.1038/s41574-021-00468-3 · DOI
  106. Korbonits, 2024, Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: part 2, specific diseases, Nat Rev Endocrinol, 20, 290, 10.1038/s41574-023-00949-7 · DOI
  107. Korbonits, 2024, Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: part 1, general recommendations, Nat Rev Endocrinol, 20, 278, 10.1038/s41574-023-00948-8 · DOI
  108. Maiter, 2024, Diagnosis and management of pituitary adenomas in children and adolescents, Eur J Endocrinol, 191, R55, 10.1093/ejendo/lvae120 · DOI
  109. Rostomyan, 2015, Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients, Endocr Relat Cancer, 22, 745, 10.1530/ERC-15-0320 · DOI · Paper page
  110. Bogusławska, 2021, Genetics of acromegaly and gigantism, J Clin Med, 10, 1377, 10.3390/jcm10071377 · DOI
  111. Brandi, 2025, Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice, Lancet Diabetes Endocrinol, 13, 699, 10.1016/S2213-8587(25)00119-6 · DOI
  112. Le Bras, 2021, Pituitary adenoma in patients with multiple endocrine neoplasia type 1: a cohort study, Eur J Endocrinol, 185, 863, 10.1530/EJE-21-0630 · DOI
  113. Chevalier, 2024, Beyond MEN1, when to think about MEN4? Retrospective study on 5600 patients in the French population and literature review, J Clin Endocrinol Metab, 109, e1482, 10.1210/clinem/dgae055 · DOI
  114. Seabrook, 2021, Multiple endocrine tumors associated with germline MAX mutations: multiple endocrine neoplasia type 5?, J Clin Endocrinol Metab, 106, 1163, 10.1210/clinem/dgaa957 · DOI
  115. Salenave, 2014, Acromegaly and McCune-Albright syndrome, J Clin Endocrinol Metab, 99, 1955, 10.1210/jc.2013-3826 · doi:10.1210/jc.2013-3826
  116. Bouys, 2021, Management of endocrine disease: carney complex: clinical and genetic update 20 years after the identification of the CNC1 (PRKAR1A) gene, Eur J Endocrinol, 184, R99, 10.1530/EJE-20-1120 · DOI

Metadata

Authors
Yogi-Morren, D., & Chanson, P.
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
2026-04-29
Volume
111
Issue
Supplement_1
Pages
S38-S50
ISSN
  • 0021-972X
  • 1945-7197
DOI
10.1210/clinem/dgag189
Cited by
3
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor, 1 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Acromegaly diagnosis. https://app.cochat.ai/papers/10.1210/clinem/dgag189
The paper
Yogi-Morren, D., & Chanson, P. (2026). Acromegaly diagnosis. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag189

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.